Brain and Mind Centre, School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, Australia.
Department of Medicine, Case Western Reserve University, Cleveland, OH, USA.
Blood Rev. 2020 Sep;43:100653. doi: 10.1016/j.blre.2020.100653. Epub 2020 Jan 17.
Neurotoxic treatments (including proteasome inhibitors, immunomodulatory drugs and vinca-alkaloids) are often used in the treatment of hematologic malignancy. Peripheral neuropathy can be part of a paraneoplastic syndrome accompanying the disease but more commonly is a consequence of treatment with neurotoxic therapies, and produces sensory, motor, autonomic nerve dysfunction or a combination, leading to pain, loss of sensation and functional disability. This review provides an update on peripheral neuropathy in hematologic malignancy, including risk factors, mechanisms and treatment options. We examine the clinical features and risk factors for peripheral neuropathy following bortezomib, thalidomide, brentuximab vedotin and vinca alkaloid treatment, as well as related compounds. We review the current data on pharmacogenetic risk factors for the development of toxicity and highlight areas of future research.
神经毒性治疗（包括蛋白酶体抑制剂、免疫调节剂和长春碱类药物）常用于血液系统恶性肿瘤的治疗。周围神经病可以是伴随疾病的副肿瘤综合征的一部分，但更常见的是神经毒性治疗的后果，产生感觉、运动、自主神经功能障碍或混合性障碍，导致疼痛、感觉丧失和功能障碍。本文就血液系统恶性肿瘤中的周围神经病进行综述，包括其危险因素、发病机制和治疗选择。我们检查了硼替佐米、沙利度胺、本妥昔单抗维达汀和长春碱类药物治疗后以及相关化合物引起的周围神经病的临床特征和危险因素。我们回顾了与毒性发生相关的药物遗传学危险因素的现有数据，并强调了未来研究的领域。
